Table 2.
Magnesium and cyclosporin A evaluation in rodent TBI models
Drug | TBI model | Route of administration | Time window | Repeated administration | Outcome measure | Time for outcome |
---|---|---|---|---|---|---|
Magnesium | lFPI1–6,13–14,16,22 | i.v.1–7,9–11,13–16,18,19,22 | Pre-injury3,22 | Yes8,18 | Cognition1,2,11,14,16,18,19,22 | ≤7 days1,6,8–10,12,13,17,18,20 |
I/A7–11,15,17,19–20 | i.p.17,20,21 | ≤1 h1,2,4–7,9–21 | No1–7,9–17,19–22 | Motor/ | 7–28 days2–5,11,14,19,21,22 | |
CHI12 | s.c.12 | 1–6 h8 | Sensorymotor2–4,6–12,14,18,19,21 | >28 days15,16 | ||
Bifrontal contusion18 | i.m.8,10 | >6 h8 | Oedema2,17,20 | |||
CCI23,24,27,28 | Lesion vol/cell death5,6,13,16,19,22 | |||||
Rat1–22 | Complex11,16 | |||||
Mouse | ||||||
Cyclosporin | lFPI25,26,28 | i.v.25,27 | Pre-injury23,25 | Yes23–26,28* | Cognition25,26 | ≤7 days23,24,27,28 |
CCI23,24,27,28 | i.p.23,26,28 | ≤1 h23,24,26,27 | No27 | Motor/Sensorymotor25,26 | 7–28 days25,26 | |
Rat25–28 | s.c.24 | 1–6 h28 | >28 days | |||
Mouse23,24 | i.m. | >6 h28 | Oedema27 | |||
Lesion vol/cell death23,24,28 | ||||||
Complex |
References to Table 2:
Overview of preclinical studies evaluating Mg2+ or cyclosporin A in rodent models of TBI.
Prolonged, >1 h infusion, included in the Repeated administration column.
CCI, controlled cortical contusion injury; CHI, closed head injury; i.m., intramuscular; i.p., intraperitoneal; i.v., intravenous; I/A, impact-acceleration; lFPI, lateral fluid percussion injury; s.c., subcutaneous; TBI, traumatic brain injury.